Table 1.
Characteristics of included randomized controlled trials
| Trial | Year | Experimental Arm | Method of PD-l testing | Treatment line | Disease site | Control Arm | Sample size |
|---|---|---|---|---|---|---|---|
| Keynote-042 | 2019 | Pembrolizumab 200 mg every 3 week |
PD-L1 IHC 22C3 pharmDx assay | 1st line | NSCLC | Platinum based combination therapy | 1274 |
| Keynote-024 | 2016 | Pembrolizumab 200 mg every 3 weeks |
PD-L1 IHC 22C3 pharmDx assay | 1st line | NSCLC | Platinum based combination therapy | 305 |
| Keynote-010 | 2015 | Pembrolizumab 2 mg/kg every 3 weeks(1.1) |
PD-L1 IHC 22C3 pharmDx assay | 2nd line | NSCLC | Docetaxel | 1034 |
| CheckMate-057 | 2015 | Nivolumab 3 mg/kg every 2 weeks |
Rabbit 28-8 (Dako) | 2nd line | NSCLC (Non-Squamous) | Docetaxel | 582 |
| CheckMate-017 | 2015 | Nivolumab 3 mg/kg every 2 weeks |
Rabbit 28-8 (Dako) | 2nd line | NSCLC (Squamous) | Docetaxel | 272 |
| CheckMate-026 | 2017 | Nivolumab 3 mg/kg every 2 weeks |
Rabbit 28-8 (Dako) | 1st line | NSCLC | Platinum based combination therapy | 541 |
| IMpower110 | 2019 | Atezolizumab 1200 mg every 3 weeks |
VENTANA SP142 IHC assay | 1st line | NSCLC (Non-Squamous) | Platinum based combination therapy | 555 |
| OAK | 2017 | Atezolizumab 1200 mg every 3 weeks |
VENTANA SP142 IHC assay | 2nd line | NSCLC | Docetaxel | 850 |
| POPLAR | 2016 | Atezolizumab 1200 mg every 3 weeks |
VENTANA SP142 IHC assay | 2nd line | NSCLC | Docetaxel | 287 |
| Javelin 200 Lung | 2018 | Avelumab 10mg /kg evey 2 weeks |
PD-L1 IHC 73-10 pharmDx assay | 2nd line | NSCLC | Docetaxel | 792 |
| Keynote-006 | 2015 | Pembrolizumab 10 mg/kg every 3 weeks (1.2) |
PD-L1 IHC 22C3 pharmDx assay | 1st line | Metastatic melanoma | Ipilimumab | 834 |
| CheckMate-067 | 2018 | Nivolumab 3 mg/kg every 2 weeks |
Rabbit 28-8 (Dako) | 1st line | Metastatic Melanoma | Ipilimumab | 631 |
| Keynote-048 | 2018 | Pembrolizumab 200 mg/kg every 3 weeks |
PD-L1 IHC 22C3 pharmDx assay | 1st line | Metastatic HNSCC | Chemotherapy+ cetuximab | 882 |
| CheckMate-141 | 2018 | Nivolumab 3 mg/kg every 2 weeks |
Rabbit 28-8 (Dako) | 1st line | Metastatic HNSCC | Single agent (methotrexate, docetaxel or cetuximab) | 361 |
| Keynote-045 | 2017 | Pembrolizumab 200 mg every 3 weeks |
PD-L1 IHC 22C3 pharmDx assay) | 2nd line | Metastatic Urothelial cancer | Chemotherapy (docetaxel, paclitaxel or vinflunine) | 542 |
| IMvigor211 | 2019 | Atezolizumab 1200 mg every 3 weeks. |
VENTANA SP142 IHC assay | 2nd line | Metastatic Urothelial cancer | Chemotherapy (docetaxel, paclitaxel or vinflunine) | 931 |
NSCLC, non-small cell lung cancer; HNSCC, head and neck squamous cell carcinoma.
1.1,: the third arm, where the pembrolizumab dose was 10mg/kg every 3 weeks was not included, due to the significant difference in dosing, compared to the standard regimen.
1.2: The third arm, where the pembrolizumab dose was 10 mg/kg every 2 weeks was not included, compared to the significant difference in dosing interval compared to the standard regimen.